David W. Boulton

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

Mark C. Petrie, Subodh Verma, Kieran F. Docherty et al. · JAMA · 2020 · 536 citations · Full text

Medicine, Cardiology, Pharmacology +17

Why do <scp>SGLT2</scp> inhibitors reduce heart failure hospitalization? <scp>A</scp> differential volume regulation hypothesis

Karen Melissa Hallow, Gabriel Helmlinger, Peter J. Greasley et al. · Diabetes Obesity and Metabolism · 2017 · 482 citations · Full text

Medicine, Cardiology, Pharmacology +17

Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

Bernard J. Komoroski, N. Vachharajani, David W. Boulton et al. · Clinical Pharmacology & Therapeutics · 2009 · 346 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

Ralph A. DeFronzo, Marcus Hompesch, Sreeneeranj Kasichayanula et al. · Diabetes Care · 2013 · 288 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

In vitro P-glycoprotein affinity for atypical and conventional antipsychotics

David W. Boulton, C. Lindsay DeVane, Heidi L. Liston et al. · Life Sciences · 2002 · 259 citations

Medicine, Pharmacokinetics, Pharmacology +11